Generic Name and Formulations:
Fesoterodine fumarate 4mg, 8mg; ext-rel tabs.
Indications for TOVIAZ:
Overactive bladder (OAB) with urge urinary incontinence, urgency, and frequency.
Swallow whole with liquid. 4mg once daily; may increase to max 8mg once daily. Severe renal impairment (CrCl<30mL/min) or concomitant potent CYP3A4 inhibitors: max 4mg/day.
Urinary or gastric retention. Uncontrolled narrow angle glaucoma.
Severe hepatic impairment: not recommended. Bladder outlet obstruction. Decreased GI motility (eg, severe constipation). Controlled narrow-angle glaucoma. Myasthenia gravis. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. Renal or hepatic impairment. Exposure to high environmental temperatures. Pregnancy. Nursing mothers.
Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin); see Adult. Additive effects with other antimuscarinic or anticholinergic agents.
Dry mouth, constipation, urinary retention/UTI, dyspepsia, dry eyes; angioedema (discontinue if occurs), CNS effects (eg, headache, dizziness, somnolence).
Hepatic (CYP2D6, CYP3A4).
Renal (primarily), fecal.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics